Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 4,663 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Respiratory Therapy Clear all
Active, not recruiting Phase 3 Interventional

Assessing Tenapanor as a Treatment of CF-related Constipation.

NCT06810167
View directory record Official record
Conditions
Cystic Fibrosis, Constipation
Interventions
Tenapanor
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 22, 2026, 4:28 AM EDT
Terminated Phase 2 Interventional Results available

Antineoplaston Therapy in Treating Patients With Stage IV Lung Cancer

NCT00003492
View directory record Official record
Conditions
Stage IV Lung Cancer
Interventions
Antineoplaston therapy (Atengenal + Astugenal)
Drug
Lead sponsor
Burzynski Research Institute
Other
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Oct 22, 2026, 4:28 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

NCT00845195
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Oct 22, 2026, 4:28 AM EDT
Terminated Phase 4 Interventional Results available

A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

NCT00461812
View directory record Official record
Conditions
Asthma
Interventions
Mometasone, Advair
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 22, 2026, 4:28 AM EDT
Completed No phase listed Observational

Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)

NCT01797367
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, HIV
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
25 Years and older
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Oct 22, 2026, 4:28 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

NCT05766267
View directory record Official record
Conditions
Tuberculosis, Pulmonary, Tuberculosis Infection
Interventions
Rifabutin, Delamanid, Bedaquiline, Moxifloxacin, Pyrazinamide, Isoniazid, Rifampin, Ethambutol
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
12 Years and older
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 22, 2026, 4:28 AM EDT
Completed Early Phase 1 Interventional

3D-Printed CPAP Masks for Children With Obstructive Sleep Apnea

NCT02261857
View directory record Official record
Conditions
Sleep Apnea, Obstructive, Craniofacial Abnormalities, Pediatric Disorder
Interventions
Personalized continuous positive airway pressure (CPAP) mask
Device
Lead sponsor
Glenn Green
Other
Eligibility
1 Year to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 16, 2020 · Synced Oct 22, 2026, 4:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

NCT07189871
View directory record Official record
Conditions
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous Cell Carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC), Sarcoma
Interventions
177Lu-BetaBart, BetaBart + unlabeled BetaBart
Drug
Lead sponsor
Radiopharm Theranostics, Ltd
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Dothan, Alabama • Grand Rapids, Michigan • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 22, 2026, 4:28 AM EDT
Completed Phase 2 Interventional

Study of Salirasib to Treat Non-Small Cell Lung Cancer

NCT00531401
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Salirasib
Drug
Lead sponsor
Concordia Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2011 · Synced Oct 22, 2026, 4:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

NCT04895709
View directory record Official record
Conditions
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Urothelial Carcinoma, Pancreatic Adenocarcinoma, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms
Interventions
BMS-986340, BMS-936558-01, Docetaxel, Pumitamig
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
11
States / cities
Clovis, California • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 22, 2026, 4:28 AM EDT
Recruiting Phase 2 Interventional

Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer

NCT07718672
View directory record Official record
Conditions
Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Lymph Node Biopsy, Positron Emission Tomography, Stereotactic Body Radiation Therapy, Survey Administration
Procedure · Radiation · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 22, 2026, 4:28 AM EDT
Terminated Phase 2 Interventional Results available

Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung Cancer

NCT03995667
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Questionnaire Administration, Tumor Treating Fields Therapy
Other · Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
22 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 22, 2026, 4:28 AM EDT
Withdrawn Phase 2 Interventional

Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas

NCT01678053
View directory record Official record
Conditions
Contact Ulcer of Vocal Folds, Granuloma of Vocal Cords, Granuloma, Laryngeal, Granuloma
Interventions
onabotulinumtoxinA, omeprazole (proton pump inhibitor)
Drug
Lead sponsor
Phillip Song, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 22, 2026, 4:28 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

NCT01222572
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Lung Cancer, NSCLC
Interventions
Stereotactic boost, Conventional RT, Etoposide, Cisplatin
Radiation · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 22, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Results available

Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)

NCT04530604
View directory record Official record
Conditions
COVID, Sars-CoV2, COVID-19, Acute Respiratory Distress Syndrome
Interventions
Defibrotide
Drug
Lead sponsor
Gregory Yanik
Other
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 22, 2026, 4:28 AM EDT
Completed Not applicable Interventional Results available

The Evaluation of the Toffee Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea

NCT03242148
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Toffee Nasal Pillows Mask
Device
Lead sponsor
Fisher and Paykel Healthcare
Industry
Eligibility
22 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Dublin, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 22, 2026, 4:28 AM EDT
Completed Phase 2 Interventional

Diagnosis and Treatment of Sleep-Disordered Breathing in the Homes of Patients With Transient Ischemic Attack

NCT00251290
View directory record Official record
Conditions
Transient Ischemic Attack, Sleep Apnea
Interventions
auto-titrating continuous positive airway pressure
Procedure
Lead sponsor
Yale University
Other
Eligibility
45 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
New Haven, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 3, 2009 · Synced Oct 22, 2026, 4:28 AM EDT
Completed No phase listed Observational

Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects

NCT03304548
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
Telephone concept elicitation interview
Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 22, 2026, 4:28 AM EDT
Recruiting Not applicable Interventional

Home-based Under Mattress Monitor for OSA

NCT07186725
View directory record Official record
Conditions
Obstructive Sleep Apnea (OSAS), Obstructive Sleep Apnea (SAOS)
Interventions
Under-mattress monitor, level 3 Home Sleep Apnea Test, Mandibular Advancement Device (MAD)
Device
Lead sponsor
Isabel Moreno Hay
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 22, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects

NCT04334460
View directory record Official record
Conditions
Sars-CoV-2, Covid19
Interventions
BLD-2660
Drug
Lead sponsor
Blade Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
27
States / cities
Irvine, California • Los Angeles, California • San Jose, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 22, 2026, 4:28 AM EDT
Active, not recruiting Phase 3 Interventional

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05721755
View directory record Official record
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Carboplatin, Cisplatin, Computed Tomography, Fluorouracil, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy
Drug · Procedure · Biological + 2 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
51
States / cities
Tampa, Florida • Atlanta, Georgia • Boise, Idaho + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 22, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)

NCT03066778
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
27
States / cities
Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2022 · Synced Oct 22, 2026, 4:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

NCT04063215
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
HB-adMSCs
Biological
Lead sponsor
Hope Biosciences LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 22, 2026, 4:28 AM EDT
Completed Phase 1 Interventional

Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

NCT02503358
View directory record Official record
Conditions
Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Selumetinib
Other · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 22, 2026, 4:28 AM EDT